. 2023 Dec 7;331(1):49–59. doi: 10.1001/jama.2023.25463

Table 3. Subgroup Analyses of Disease-Free Survival in Patients Who Had a Pregnancy (vs Patients With No Pregnancy).

Variables	No. of patients/No. of events	Univariate hazard ratio (95% CI)	P value	Multivariate hazard ratio (95% CI)	P value
Study group	4732/1683	0.97 (0.82-1.15)	.74	0.99 (0.81-1.20)	.90
Specific BRCA gene
BRCA1	3033/1101	0.79 (0.64-0.97)	<.001^a	0.80 (0.63-1.01)	.007^a
BRCA2	1663/569	1.61 (1.22-2.12)		1.55 (1.12-2.16)
BRCA1 and BRCA2	26/11	1.82 (0.33-10.1)		4.49 (0.28-72.17)
BRCA, unknown if BRCA1 or BRCA2	10/2	1.11 (0.05-23.2)		NE
Hormone receptor status
Positive	2126/715	1.29 (0.98-1.70)	.04^a	1.30 (0.95-1.76)	.009^a
Negative	2529/951	0.82 (0.67-1.01)		0.76 (0.60-0.95)
Unknown	77/17	1.08 (0.25-4.74)		0.28 (0.04-2.21)
ERBB2 status
Positive	339/111	0.66 (0.24-1.80)	.30^a	0.61 (0.22-1.71)	.08^a
Negative	4151/1471	1.01 (0.85-1.21)		1.07 (0.87-1.31)
Unknown	242/101	0.61 (0.30-1.26)		0.42 (0.17-1.02)
Chemotherapy
No chemotherapy	381/138	1.06 (0.61-1.87)	.31^a	0.77 (0.39-1.52)	.47^a
(Neo)adjuvant chemotherapy	4319/1534	0.97 (0.82-1.16)		1.00 (0.82-1.23)
Unknown	32/11	NE		0.77 (0.39-1.52)
Endocrine therapy
No endocrine therapy	2640/998	0.82 (0.67-1.01)	.02^a	0.85 (0.67-1.08)	.01^a
Endocrine therapy	1987/659	1.35 (1.01-1.81)		1.55 (1.08-2.21)
Unknown	105/26	0.77 (0.18-3.23)		0.13 (0.01-2.95)

Abbreviation: NE, not evaluable.

^{^a}

P value for interaction.